DrugPatentWatch Database Preview

Details for Patent: 8,524,773

« Back to Dashboard

Which drugs does patent 8,524,773 protect, and when does it expire?

Patent 8,524,773 protects TECFIDERA and is included in one NDA.

This patent has forty-seven patent family members in thirty-one countries.

Summary for Patent: 8,524,773

Title:	Utilization of dialkylfumarates
Abstract:	The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
Inventor(s):	Joshi; Rajendra Kumar (Zurich, CH), Strebel; Hans-Peter (Muri, CH)
Assignee:	Biogen Idec International GmbH (Zug, CH)
Application Number:	13/612,221
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 8,524,773

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Biogen Idec Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013		RX	Yes	No						METHOD OF TREATING MULTIPLE SCLEROSIS
Biogen Idec Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-002	Mar 27, 2013		RX	Yes	Yes						METHOD OF TREATING MULTIPLE SCLEROSIS

Foreign Priority and PCT Information for Patent: 8,524,773

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	198 53 487	Nov 19, 1998

Non-Orange Book US Patents Family Members for Patent 8,524,773

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,612,110	Utilization of dialkylfumarates
7,619,001	Utilization of dialkylfumarates
7,803,840	Utilization of dialkylfumarates
6,509,376	Utilization of dialkyfumarates

International Patents Family Members for US Patent 8,524,773

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	242633
Australia	1157200
Australia	752733
Bulgaria	105396